Cancer research
Researchers from Northwestern University have presented fresh data on the use of artificial intelligence (AI) algorithms to analyze radiomic features in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy. The study analyzed data from 159 stage III-IV NSCLC patients and found that radiomics models could predict the occurrence of checkpoint
Cancer
Research from Hangzhou Normal University, in collaboration with various institutions, has shed light on potential therapeutic targets for gastric cancer, a disease with poor prognosis and limited treatment options. The study focused on understanding the inflammatory and protein-protein interaction hub networks that drive tumor progression. By analyzing gene expression and
Cancer
Scientists at Fudan University in Shanghai, China, have made a groundbreaking discovery in cancer therapy, finding that high-intensity focused ultrasound (HIFU) can convert "cold" tumors into "hot" ones, making them more responsive to immunotherapy. The study, published in Acta Pharmaceutica Sinica B, investigated the role of
Cancer
Researchers have made a significant breakthrough in the field of cancer immunotherapy, utilizing optogenetics to refine the precision and adaptability of this treatment approach. A new study published in Essays in Biochemistry reveals the potential of optogenetics to improve the safety and efficacy of cancer immunotherapy by enabling targeted modulation
Cancer
A groundbreaking new study published in the journal Nature Cancer reveals that radiation therapy can overcome immunotherapy resistance in certain cancers, offering new hope for patients whose tumors have become resistant to treatment. Researchers from the Johns Hopkins Kimmel Cancer Center and the Netherlands Cancer Institute found that combining radiation
Cancer research
Researchers at Zhengzhou University have developed a novel peptide-based nanoparticle, Smac-D1@Taz, that shows promise in enhancing antigen presentation in cancer stem cells, leading to improved cancer treatment outcomes. By combining the PD-L1 antagonist PPA-1 with the Smac peptide, which enhances radiosensitivity, and the small molecule Tazemetostat (Taz), which upregulates
Cancer research
New research on Immunology-Immunoglobulins highlights the integration of novel antibody-mediated targeted therapies into both relapsed/refractory (R/R) and frontline pediatric acute lymphoblastic leukemia (ALL) treatment protocols, leading to critical advancements in the field. Researchers at the University of Texas MD Anderson Cancer Center are exploring targeted therapies that attack
Cancer
Researchers at the University of Florida have made a breakthrough in cancer treatment by pairing an experimental mRNA vaccine with common anticancer drugs. The study, published in Nature Biomedical Engineering, showed that the pairing triggered a strong antitumor response in mouse models of melanoma, skin, bone, and brain cancers. The
Cancer research
Cambridge University Hospitals and the National Institute for Health and Care Research (NIHR) are piloting a novel scheme to speed up clinical trials, enabling more patients to benefit from immunotherapy treatments for pancreatic cancer. The 'Just in Time' scheme aims to reduce clinical trial setup time from months
Cancer research
Researchers from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, have identified a five-gene signature associated with prognosis and immune regulation in glioblastoma patients. The study, which analyzed bulk and single-cell RNA sequencing data, revealed that the signature was significantly associated with worse survival outcomes and
Cancer research
Researchers at the Affiliated People's Hospital in Fujian, People's Republic of China, have reported a significant breakthrough in cancer gene therapy, using a genetically modified oncolytic adenovirus called H101 to treat advanced esophageal squamous cell carcinoma (ESCC). The study, published in Frontiers in Immunology, demonstrated the
Cancer
Researchers at Sichuan Cancer Hospital and Research Institute, along with Liaoning Cancer Hospital & Institute, are conducting a Phase 3 clinical trial to examine the effectiveness of tislelizumab combined with chemotherapy for patients with MHC Class II-positive locally advanced gastric or gastroesophageal junction adenocarcinoma. The study is inspired by previous
